A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone Furoate/Formoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Adolescents and Adults With Persistent Asthma (Protocol No. P06241 Also Known as P202)

Trial Profile

A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone Furoate/Formoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Adolescents and Adults With Persistent Asthma (Protocol No. P06241 Also Known as P202)

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Feb 2017

At a glance

  • Drugs Mometasone/formoterol (Primary) ; Mometasone
  • Indications Asthma
  • Focus Adverse reactions
  • Acronyms SPIRO
  • Sponsors Merck & Co; Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 16 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 09 Nov 2016 This trial has been completed in Slovakia (End date:2016-10-11) as per European Clinical Trials Database record.
    • 27 Oct 2016 Planned End Date changed from 1 Oct 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top